Introgen´s proprietary nanoparticle vector technology combines DNA with the lipids DOTAP and cholesterol to create a synthetic delivery vehicle. The nanoparticle vectors have broad utility in the development of systemic cancer therapies:
- The nanoparticle vector system is compatible with any tumor suppressor.
The nanoparticle lipid-DNA complex is formulated as particles of lipid surrounding DNA which encodes a tumor suppressor with therapeutic potential. The complex is then extruded to form nanoscale particles.
When administered to the body, via direct injection to tumors or intravenously, the vector binds to cell membranes, which also are composed of lipids. The lipid in the delivery system fuses with the cell membrane, leading to uptake of the particle into the cell. Normal cellular processes degrade the lipid, and the DNA is taken into the nucleus and expressed, producing a therapeutic protein that induces anti-cancer effects.
Introgen’s product development candidate INGN 401, currently in Phase 1 clinical trials with an intravenous route of delivery, and INGN 402 and INGN 403, currently in pre-clinical development, utilize the Company’s nanoparticle delivery technology.
